- Home
- KSS vs ETNB Comparison
KSS vs ETNB Comparison
Compare KSS & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KSS
- ETNB
- Stock Information
- Founded
- KSS 1962
- ETNB 2018
- Country
- KSS United States
- ETNB United States
- Employees
- KSS N/A
- ETNB N/A
- Industry
- KSS Department/Specialty Retail Stores
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- KSS Consumer Discretionary
- ETNB Health Care
- Exchange
- KSS Nasdaq
- ETNB Nasdaq
- Market Cap
- KSS 1.4B
- ETNB 1.0B
- IPO Year
- KSS 1992
- ETNB 2019
- Fundamental
- Price
- KSS $7.07
- ETNB $6.94
- Analyst Decision
- KSS Sell
- ETNB Strong Buy
- Analyst Count
- KSS 12
- ETNB 10
- Target Price
- KSS $9.91
- ETNB $27.56
- AVG Volume (30 Days)
- KSS 13.8M
- ETNB 1.9M
- Earning Date
- KSS 05-29-2025
- ETNB 05-08-2025
- Dividend Yield
- KSS 23.02%
- ETNB N/A
- EPS Growth
- KSS N/A
- ETNB N/A
- EPS
- KSS 0.98
- ETNB N/A
- Revenue
- KSS $16,221,000,000.00
- ETNB N/A
- Revenue This Year
- KSS N/A
- ETNB N/A
- Revenue Next Year
- KSS N/A
- ETNB N/A
- P/E Ratio
- KSS $7.20
- ETNB N/A
- Revenue Growth
- KSS N/A
- ETNB N/A
- 52 Week Low
- KSS $6.04
- ETNB $4.16
- 52 Week High
- KSS $28.25
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- KSS 44.51
- ETNB 51.15
- Support Level
- KSS $6.63
- ETNB $6.55
- Resistance Level
- KSS $7.36
- ETNB $7.09
- Average True Range (ATR)
- KSS 0.67
- ETNB 0.61
- MACD
- KSS 0.17
- ETNB 0.23
- Stochastic Oscillator
- KSS 58.57
- ETNB 94.88
About KSS Kohl's Corporation
Kohl's operates about 1,176 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 26% of its 2023 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).